<div class="headers"><div>Figure 4. Least square mean difference of percent change from baseline (95% CI) at week 24 presented by patient subgroup for (A) LDL-C (b quantiﬁcation) and (B) HDL-C for anacetrapib 100 mg versus placebo comparisonThe vertical dashed line indicates the overall treatment effect: *28.9. (n=n1, n2): n1= the number of patients in the anacetrapib 100 mg group. n2=the number of patients in the placebc group.</div><div>The vertical dashed line indicates the overall treatment effect: 94.7. (n=n1, n2):n1=the number of patients in the anacetrapib 100 mg group. n2=the number of patients in the placebo group.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Figure 4. Least square mean difference of percent change from baseline (95% CI) at week 24 presented by patient subgroup for (A) LDL-C (b quantiﬁcation) and (B) HDL-C for anacetrapib 100 mg versus placebo comparison</p></td>
<td style='border-top: 2px solid grey; text-align: left;'></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">The vertical dashed line indicates the overall treatment effect: *28.9. (n=n1, n2): n1= the number of patients in the anacetrapib 100 mg group. n2=the number of patients in the placebc group.</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">The vertical dashed line indicates the overall treatment effect: 94.7. (n=n1, n2):n1=the number of patients in the anacetrapib 100 mg group. n2=the number of patients in the placebo group.</p></td>
</tr>
</tbody>
</table>
